Previous 10 | Next 10 |
Creates Sustainable Generics Growth Engine with Approximately 25+ Launches Expected in 2021 and 2022 Expands Brand Portfolio with Addition of 505(b)(2) Pipeline and Enhances Scale of CDMO Business Purchase Price of $163.5 Million, including $89.5 Million in Cash and $74 Millio...
ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced that ANI's Board of Directors granted non-qualified inducement stock options to purchase an aggregate of 27,006 shares of ANI's common stock to Ori Gutwerg, ANI’s Senior ...
-- Key additions deepen commercial and manufacturing expertise and position Company to capture full potential across businesses -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the addition of three key pharmaceutic...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2020 financial results on Tuesday, March 9, 2021. Nikhil Lalwani, President and Chief Executive Officer, and S...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug Administration’s (“FDA”) approval of the Company’s prior appro...
ANI Pharmaceuticals (ANIP) announces FDA approval and the launch of Aminocaproic Acid Tablets USP, 500mg.The current annual U.S. market for this product is ~$12.7M, according to IQVIA/IMS Health. Aminocaproic Acid Tablets are useful in enhancing hemostasis when fibrinolysis contributes to ble...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid Tablets USP, 500mg. The current annual U.S. market for this product is approximately $12.7 m...
ANI Pharmaceuticals, Inc. (ANIP) Q3 2020 Results Earnings Conference Call November 5, 2020, 10:30 AM ET Company Participants Lisa Wilson - In-Site Communications, IR Nikhil Lalwani - President and CEO Stephen Carey - Chief Financial Officer Conference Call Participants Dana Flanders - Guggenh...
Image source: The Motley Fool. ANI Pharmaceuticals Inc (NASDAQ: ANIP) Q3 2020 Earnings Call Nov 5, 2020 , 10:30 a.m. ET Operator Continue reading For further details see: ANI Pharmaceuticals Inc (ANIP) Q3 2020 Earnings Call Transcript
ANI Pharmaceuticals (ANIP): Q3 Non-GAAP EPS of $0.97 beats by $0.09; GAAP EPS of $0.04 beats by $0.14.Revenue of $52.98M (+3.2% Y/Y) beats by $1.48M.Press Release For further details see: ANI Pharmaceuticals EPS beats by $0.09, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....